Evidence map›Paper›PMID 39757131›Full record

ArticleJournal of cellular and molecular medicine2025

Integrating Ultrabright Polymer Dots and Stereo NIR-II Imager for Assessing Anti-Angiogenic Drugs in Oral Cancer Model.

Bo-Han Huang, Fang-Yu Li, Shih-Po Su, Chiung-Tong Chen, Kuo-Wei Chang, Muh-Hwa Yang, Min-Chieh Chen, Huihua Kenny Chiang, Yang-Hsiang Chan, Yi-Jang Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bo-Han HuangDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Fang-Yu LiDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Shih-Po SuDepartment of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Chiung-Tong ChenInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan.
Kuo-Wei ChangDepartment of Dentistry, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Muh-Hwa YangInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Min-Chieh ChenDepartment of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Huihua Kenny ChiangDepartment of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Yang-Hsiang ChanDepartment of Applied Chemistry, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Yi-Jang LeeDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.ORCID 0000-0002-0340-7557

Funding

National Science and Technology Council, Taiwan 109-2314-B-010-021-MY3National Science and Technology Council, Taiwan 110-2124-M-A49A-501
6 · The paper itself

Abstract

The development of efficient platforms for the evaluation of anti-angiogenic agents is critical in advancing cancer therapeutics. In this study, we exploited an ultrabright semiconducting polymer dots (Pdots) integrating with a three-dimensional (3D) near-infrared-II (NIR-II) fluorescence imaging system designed to assess the efficacy of potent anti-angiogenic agents PX-478 and BPR0C261 in an oral squamous cell carcinoma (OSCC) tumour model, which depends on angiogenesis for dissemination. PX-478, a hypoxia-inducible factor-1α (HIF-1α) inhibitor, and BPR0C261, a microtubule-disrupting agent, were administrated into tumour-bearing mice established using murine MTCQ1 tongue cancer cells through intraperitoneal injection and oral gavage, respectively. Our findings showed that PX-478 and BPR0C261 significantly inhibited tumour growth and extended the life span of tumour-bearing mice without decreasing the body weights. The Pdots-based NIR-II vascular imaging demonstrated that the tumour vascularity was suppressed by PX-478 and BPRC0261. Accordingly, the excised tumours treated with anti-angiogenic agents showed less blood vessels than that treated with vehicles. The expression of endothelial markers CD31 was also found to be reduced in tumours treated with PX-478 and BPRC0261 using immunohistochemical (IHC) staining and Western blot analysis. Furthermore, PX-478 could suppress the expression of HIF-1α and vascular endothelial growth factor-A (VEGF-A), but BPRC0261 only suppressed VEGF-A. Taken together, this innovative 3D NIR-II imaging system combining the biocompatible Pdots with unique optical specificity enables non-invasive, real-time monitoring the efficacy of anti-angiogenic compounds.

Indexed as

Angiogenesis InhibitorsMouth NeoplasmsNeovascularization, PathologicPolymersAnimalsCarcinoma, Squamous CellCell Line, TumorDisease Models, AnimalHumansHypoxia-Inducible Factor 1, alpha SubunitMiceMice, Inbred BALB COptical ImagingStilbenesVascular Endothelial Growth Factor AAngiogenesis InhibitorsfosbretabulinHypoxia-Inducible Factor 1, alpha SubunitPolymersStilbenesVascular Endothelial Growth Factor A3D NIR‐II fluorescence imaging systemanti‐angiogenic agentsBPR0C261HIF‐1αpolymer dotstumour vascularity

Identifiers

PMID39757131
PMCPMC11702377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.